ERRATUM

Erratum to: Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials

Matteo Monami¹ · Ilaria Dicembrini¹ · Edoardo Mannucci¹

Published online: 11 October 2016
© Springer-Verlag Italia 2016

Erratum to: Acta Diabetol
DOI 10.1007/s00592-016-0892-7

In the original publication, figure 4 caption and figure 8 were wrongly published. The corrected Figs. 4 and 8 are provided here.

The online version of the original article can be found under
doi:10.1007/s00592-016-0892-7.

✉ Matteo Monami
matteo.monami@unifi.it

Edoardo Mannucci
edoardo.mannucci@unifi.it

¹ Diabetology, Azienda Ospedaliero-Universitaria Careggi,
Careggi Teaching Hospital, University of Florence, Via delle
Oblate 4, 50141 Florence, Italy

Fig. 4 Subgroup analyses for all-cause mortality considering trials with and without cardiovascular endpoints (**a** all randomised clinical trials; **b** only molecules and doses approved by FDA and/or EMA;

c sensitivity analysis with continuity correction). *SGLT2i* sodium-glucose transporter 2 inhibitors

Fig. 8 Subgroup analyses for cardiovascular mortality (**a**), myocardial infarction (**b**), and stroke (**c**) considering placebo-controlled trials with and without cardiovascular endpoints. *SGLT2i* sodium-glucose transporter 2 inhibitors *with EMPAREG and **without EMPAREG